DE68900356D1 - Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt. - Google Patents

Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.

Info

Publication number
DE68900356D1
DE68900356D1 DE8989109381T DE68900356T DE68900356D1 DE 68900356 D1 DE68900356 D1 DE 68900356D1 DE 8989109381 T DE8989109381 T DE 8989109381T DE 68900356 T DE68900356 T DE 68900356T DE 68900356 D1 DE68900356 D1 DE 68900356D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
composition containing
dihydropyridine derivative
dihydropyridine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8989109381T
Other languages
English (en)
Inventor
Ltd Miyajima
Ltd Yamaguchi
Takao Nissan Chemic Tsunematsu
Toshihisa Nissan Chemical Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Original Assignee
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd, Nissan Chemical Corp filed Critical Zeria Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE68900356D1 publication Critical patent/DE68900356D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8989109381T 1988-05-30 1989-05-24 Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt. Expired - Fee Related DE68900356D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13226288 1988-05-30
JP1050471A JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物

Publications (1)

Publication Number Publication Date
DE68900356D1 true DE68900356D1 (de) 1991-11-28

Family

ID=26390939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8989109381T Expired - Fee Related DE68900356D1 (de) 1988-05-30 1989-05-24 Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.

Country Status (8)

Country Link
US (1) US4983593A (de)
EP (1) EP0344603B1 (de)
JP (1) JP2528706B2 (de)
CA (1) CA1332152C (de)
DE (1) DE68900356D1 (de)
ES (1) ES2051920T3 (de)
GR (1) GR3003615T3 (de)
NZ (1) NZ229309A (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212139B (de) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
KR100457273B1 (ko) * 1996-03-18 2005-04-08 닛산 가가쿠 고교 가부시키 가이샤 에포니디핀염산염제제의제조방법
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
EP0901786B1 (de) 1997-08-11 2007-06-13 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1745774A3 (de) 1997-08-11 2007-04-11 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027887B1 (de) * 1999-02-10 2008-08-13 Pfizer Products Inc. Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
JP2003518038A (ja) * 1999-12-20 2003-06-03 ニコラス, ジェイ カークホフ, 流動床噴霧乾燥によるナノ粒子製造方法
EP1712222A3 (de) * 1999-12-23 2012-06-20 Pfizer Products Inc. Arzneizusammensetzung mit erhöhter Arzneistoffkonzentration
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
ATE409462T1 (de) 2004-05-28 2008-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
WO2006064906A1 (ja) * 2004-12-17 2006-06-22 Ono Pharmaceutical Co., Ltd. 非晶質性組成物
EP1923051A4 (de) * 2005-09-06 2012-12-19 Astellas Pharma Inc Mikroteilchen einer schwerlöslichen substanz mit enterischem basismaterial, das auf der oberfläche der substanz adsorbiert ist
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Npyy5受容体拮抗剤を含有する固形製剤
JPWO2009072334A1 (ja) * 2007-12-03 2011-04-21 富田製薬株式会社 製剤用核粒子
US20110065800A1 (en) 2008-05-14 2011-03-17 Haihong Fan Formulations for cathepsin k inhibitors
CN105237530A (zh) 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110064806A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
KR101807338B1 (ko) 2010-06-14 2018-01-10 다우 글로벌 테크놀로지스 엘엘씨 아세테이트 및 석신에이트 치환이 향상된 하이드록시프로필 메틸 셀룰로즈 아세테이트 석신에이트
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP2014507424A (ja) 2011-03-08 2014-03-27 ザリカス ファーマスーティカルズ リミテッド 固体分散物製剤およびその使用方法
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2837391B1 (de) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
CA2935307C (en) 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018175648A1 (en) * 2017-03-21 2018-09-27 Bioduro, Llc Gastrointestinal-protective formulations for oral delivery of proteins and peptides
EP3841086A4 (de) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948810A (ja) 1982-09-10 1984-03-21 Sony Corp 磁性記録体におけるデ−タのマスク及び再生方法
JPS62123117A (ja) 1985-11-22 1987-06-04 Nippon Chemiphar Co Ltd 塩酸ニカルジピン経口用組成物
CN1016063B (zh) * 1986-01-22 1992-04-01 日产化学工业株式会社 二氢吡啶-5-膦酸环亚丙基酯的制备
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation

Also Published As

Publication number Publication date
NZ229309A (en) 1991-06-25
JP2528706B2 (ja) 1996-08-28
JPH0249728A (ja) 1990-02-20
CA1332152C (en) 1994-09-27
US4983593A (en) 1991-01-08
EP0344603B1 (de) 1991-10-23
EP0344603A1 (de) 1989-12-06
ES2051920T3 (es) 1994-07-01
GR3003615T3 (de) 1993-03-16

Similar Documents

Publication Publication Date Title
DE68900356D1 (de) Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.
DE68901417D1 (de) Pharmazeutische zusammensetzung.
DE122004000023I2 (de) Pharmazeutische Zusammensetzung
FI892640A (fi) Menetelmä piperidinoalkanoli-ibuprofeeniyhdistelmää sisältävän farmaseuttisen koostumuksen valmistamiseksi
DE3868986D1 (de) Pharmazeutische zusammensetzungen.
DK229489D0 (da) Laegemiddeladsorbater
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
FI901102A0 (fi) Farmaceutiska kompositioner.
FI893340A (fi) Foerfarande foer att erhaolla farmaceutiska sammansaettningar foer att hindra smittbara koenssjukdomar.
DE69006094D1 (de) Pharmazeutische Zusammensetzungen.
IT8820386A0 (it) Composizioni farmaceutiche orosolubili contenti acetilcisteina.
NL192832B (nl) 1,8 gebrugde 6-halogeen-4-chinolon-3-carbonzuurderivaten en farmaceutisch preparaat dat een dergelijk derivaat bevat.
FI893643A (fi) Farmaceutiska kompositioner.
DE68918847D1 (de) Stabile pharmazeutische zusammensetzung.
IT1216822B (it) Composizioni farmaceutiche a basedi chetotifene
NL194827B (nl) Thieno-triazolo-diazepinederivaten en farmaceutische preparaten die een dergelijk derivaat bevatten.
DK128589D0 (da) Anvendelse af piperidinmethanolderivater til fremstilling af et farmaceutisk praeparat
EP0406739A3 (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
ATA225988A (de) Selbstfaerbestempel
IT1221493B (it) Composizioni farmaceutiche a cessione ritardata
ATE102034T1 (de) Ein piperidinylalkanolantihistaminikum enthaltende fluessige arzneizubereitungen.
DE68915203D1 (de) Pharmazeutische Mischungen.
ATA133288A (de) Pharmazeutische zusammensetzung
DE58905160D1 (de) Pharmazeutische zubereitung.
ATE68699T1 (de) Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee